International Nosocomial Infection Control Consortium (INICC) report, data summary of 45 countries for 2013- 2018, Adult and Pediatric Units, Device-associated Module.

Rosenthal V. D., Duszynska W., Ider B., Gurskis V., Ruzzieh M. A. A., Myatra S. N., ...Daha Fazla

American journal of infection control, cilt.49, ss.1267-1274, 2021 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 49
  • Basım Tarihi: 2021
  • Doi Numarası: 10.1016/j.ajic.2021.04.077
  • Dergi Adı: American journal of infection control
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, PASCAL, BIOSIS, CAB Abstracts, CINAHL, EMBASE, MEDLINE, Veterinary Science Database
  • Sayfa Sayıları: ss.1267-1274
  • Anahtar Kelimeler: Key Hospital infection, Nosocomial infection, Health care-associated infection, Device-associated infection, Bacterial resistance, Limited resources countries, INTENSIVE-CARE UNITS, BLOOD-STREAM INFECTION, VENTILATOR-ASSOCIATED PNEUMONIA, MULTIDIMENSIONAL APPROACH, SOCIOECONOMIC IMPACT, ATTRIBUTABLE COST, CONTROL STRATEGY, HOSPITAL STAY, 10 CITIES, RATES
  • Eskişehir Osmangazi Üniversitesi Adresli: Evet

Özet

Background: We report the results of INICC surveillance study from 2013 to 2018, in 664 intensive care units (ICUs) in 133 cities, of 45 countries, from Latin-America, Europe, Africa, Eastern-Mediterranean, Southeast-Asia, and Western-Pacific. Methods: Prospective data from patients hospitalized in ICUs were collected through INICC Surveillance Online System. CDC-NHSN definitions for device-associated healthcare-associated infection (DA-HAI) were applied. Results: We collected data from 428,847 patients, for an aggregate of 2,815,402 bed-days, 1,468,216 central line (CL)-days, 1,053,330 mechanical ventilator (MV)-days, 1,740,776 urinary catheter (UC)-days. We found 7,785 CL-associated bloodstream infections (CLAB), 12,085 ventilator-associated events (VAE), and 5,509 UC-associated uri-nary tract infections (CAUTI). Pooled DA-HAI rates were 5.91% and 9.01 DA-HAIs/1,000 bed-days. Pooled CLAB rate was 5.30/1,000 CL-days; VAE rate was 11.47/1,000 MV-days, and CAUTI rate was 3.16/1,000 UC-days. P aeru-ginosa was non-susceptible (NS) to imipenem in 52.72% of cases; to colistin in 10.38%; to ceftazidime in 50%; to ciprofloxacin in 40.28%; and to amikacin in 34.05%. Klebsiella spp was NS to imipenem in 49.16%; to ceftazidime in 78.01%; to ciprofloxacin in 66.26%; and to amikacin in 42.45%. coagulase-negative Staphylococci and S aureus were NS to oxacillin in 91.44% and 56.03%, respectively. Enterococcus spp was NS to vancomycin in 42.31% of the cases. Conclusions: DA-HAI rates and bacterial resistance are high and continuous efforts are needed to reduce them. (c) 2021 Published by Elsevier Inc. on behalf of Association for Professionals in Infection Control and Epidemiology, Inc.